Novo Nordisk 'B'

Morgan Stanley cut Novo Nordisk from Equal-Weight to Underweight and kept the price target at DKK 250, saying the valuation does not reflect the muted medium‑term growth outlook. Analyst Thibault Boutherin points to the patent expiry of semaglutide in the early 2030s, which could create significant headwinds, even though the weight‑loss pill will account for much of 2026 sales. The stock fell more than 2% and broke short‑term supports; Morgan Stanley expects no new catalysts from the capital markets day on Sept. 21, so future gains are likely to depend more on larger acquisitions or mergers. » Más en deraktionaer.de

European stocks recovered modestly, with the EuroStoxx 50 up about 0.6%, but investors remain cautious due to the Middle East conflict and high oil prices. US consumer prices are in focus this afternoon as an important influence on the Fed’s rate decision. Novo Nordisk fell 2.2% after Morgan Stanley downgraded the stock to "Underweight," citing weaker medium-term growth prospects and a looming patent expiry for semaglutide. Banks and insurers led the sectors, while chemicals were the weakest sector. » Más en finanzen.net

A downgrade by Morgan Stanley to "Underweight" with an unchanged price target of 250 kroner sent the Novo Nordisk share down about 2.5% to roughly 279 kroner. Analyst Thibault Boutherin criticizes that the valuation does not sufficiently reflect mid-term weak growth prospects and the looming patent expiry risk for semaglutide in the early 2030s. He expects that the success of the weight‑loss drug will not fully offset the headwinds and sees only limited catalysts for the investment story, unless there were a larger takeover; the capital markets event on 21 September comes into focus. » Más en finanzen.net